foto london banner.jpg

Something Powerful

Tell The Reader More

The headline and subheader tells us what you're offering, and the form header closes the deal. Over here you can explain why your offer is so great it's worth filling out a form for.

Remember:

  • Bullets are great
  • For spelling out benefits and
  • Turning visitors into leads.

Investor interview with Mark Barnett

Biotech and Money recently caught up with Mark Barnett, Head of UK Equities...

Read More

Announcing Brand New Agenda for 2nd Annual Biotech...

What do the Global BD heads of GSK, AstraZeneca, rockstar investors like Si...

Read More

Oxford AHSN’s role in developing special networks

Prof. Gary Ford CBE, talks through what OAHSN is doing to break down tradit...

Read More

Francois Martelet, CEO and his aim for NetScientif...

3 months into his tenure as CEO of NetScientific, the vastly experienced in...

Read More

Licensing and Partnerships: What Pharma want

The following transcript comes from Licensing and Partnerships: What Pharma...

Read More

Presenting scientific leadership and a clear focus

Shaun Grady, VP, BD Operations, Astrazeneca.Shaun is responsible for broade...

Read More

‘Biotechs and the City' Licensing & Partnerships

‘Biotechs and the City – Licensing and Partnerships’ was the latest in a se...

Read More

CRT’s stateside licencing and partnering activity

Dr Larry Steranka, Managing Director, CRT Inc. established CRT Inc. in 2006...

Read More

R&D alliance, option and licence agreements and BM...

Sam has been CEO of Modern Biosciences since 2007, prior to which he was a ...

Read More

Sneak Preview! Collaboration Innovation - J&J's bo...

For the upcoming August issue of our Drugs&Dealers Magazine, Biotech and Mo...

Read More

Brilliant biopharma partnerships: 7 Tips

This is the last post in a 3 part series on biotech and pharma partnerships...

Read More

Another 7 tips to creating brilliant biopharma par...

We all know that partnerships are the lifeblood of the biopharma industry. ...

Read More

Add Your Response